Clinical Trial Update: A Study of the IGF-1R Inhibitor AXL1717 in Combination With Gemcitabine HCL and Carboplatin to Treat Non-small-cell Lung Cancer (NSCLC) [Phase 1]

View source ↗

Summary

This ClinicalTrials.gov update reports a Phase 1 study evaluating the IGF-1R inhibitor AXL1717 in combination with gemcitabine and carboplatin for non-small cel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AXL1717 (AXL1717)
• CARBOPLATIN (Carboplatin)
• Gemcitabine HCl (gemcitabine)

Snippet

Sponsor: Axelar AB | Conditions: Non Small Cell Lung Cancer | Phase 1 | Status: COMPLETED